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Introduction
Lung and bronchus cancer are the leading causes of cancer-related deaths in the
United States, representing 13.2% of all new cancer cases in the U.S. In 2010-2014,
new cases of lung cancer was 55.8 per 100,000 men and women per year and the
number of deaths was 44.7 per 100,000 men per year (SEER 2016). Based on data
collected between 2007-2013 by the SEER program of the NIH Nation Cancer Institute,
only 18.1% of people diagnosed with lung and bronchus cancer survive 5 or more years
and in 2017, it is estimated that there will be 222,500 new cases of lung and bronchus
cancer and 155,870 people will die from the diseases (SEER 2016).
The problem with common cancer treatments, surgery, chemotherapy, and
radiation therapy, is that they are too invasive and cause damage to neighboring noncancerous cells. Many new cancer treatments use targeted therapy for treating diverse
types of cancer by taking advantage of specific proteins found in cancer cells but not in
healthy tissues and block cancer cell survival signals.
Bruton’s tyrosine kinase (BTK) is a Tec family kinase whose native form, BTK-A,
is commonly found and directly involved in B lymphocyte development, signaling, and
survival (Wang 2016). Mutation of the BTK coding gene, Btk, can cause X-linked
agammaglobulinemia, a genetic disorder that results in low levels of mature B cells,
resulting in severely compromised immune functionality in patients lacking a functional
Btk gene (Honihberg 2010).
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BTK-A is the native form of the
tyrosine kinase found in B lymphocytes.
BTK-C is an alternate isoform of BTK
transcribed from an alternate promoter,
resulting in an amino-terminus extension in
the protein. This isoform of BTK has been
found to be expressed at low levels in breast
and prostate cancer cells as a survival

Figure 1. The structure of Bruton’s Tyrosine
Kinase

factor (Eifert 2013; Kokabee 2015).

Figure 2. The BTK-C isoform contains an Nterminus extension.

In B-lymphocytes, BTK is a cytosolic kinase typically found in its inactive,
unphosphorylated form, but upon activation, it affects other downstream proteins such
as EGFR and AKT growth factors and innate immune response receptors. (Akinleye,
Chen, Mukhi, Song, & Liu, 2013). This initiates a variety of cellular processes such as
survival and proliferation, motility, cytokine production, and antigen presentation. Known
BTK inhibitors, ibrutinib and AVL-292, have been shown to block the phosphorylation of
BTK at the Tyr-223 residue and inhibit the downstream effects of the growth factors,
reducing cell proliferation. Due to its safeness and bioavailability, Ibrutinib is currently
being used in Phase III clinical trials for treating patients with B-cell neoplasms
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(Akinleye, Chen, Mukhi, Song, & Liu, 2013) Dosages of 420 and 840 mg/day of ibrutinib
are well tolerated.

Figure 3. Inhibition of BTK affects downstream proteins that mediate cell survival.

Evidence shows BTK to be a target therapeutic in treating patients with nonHodgkin B cell lymphoma (NHL), rheumatoid arthritis (RA), and breast cancer (Herman
2011). In HER2-positive breast cancer cells have been shown to be inhibited by not only
its known inhibitor, lapatinib, but also by ibrutinib as well due to BTK inhibition and
blockage of the AKT signaling pathway (Wang 2015). Recent evidence has shown BTKC to be expressed in prostate cancer as well, and known inhibitors of BTK, such as
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ibrutinib and AVL-292, have been shown to block BTK-C and prevent cancer cell
proliferation (Kokabee 2015).
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Figure 4. Molecular structure of BTK small molecule inhibitors

The goal of the research was to investigate whether BTK-C is expressed in lung
cancer cells in the same manner as prostate or breast cancer cells. Through Next
Generation RNA Sequencing of various lung cancer cell line transcriptomes, there has
been shown high levels of BTK-C expressed in lung cancer cells (Figure 5). If BTK-C is
expressed in lung cancer cells, then the tyrosine kinase can act as a potential
therapeutic target for treating lung cancer. By blocking BTK-C activity with its known
inhibitors, there may be a reduction in cell survival in BTK expressing lung cancer cells.
Some non-small cell lung cancer cells (NSCLC) express high levels of EGFR and
inhibition by erlotinib, a small molecule inhibitor, may also have an effect on cell
proliferation. Other growth factors, such as HER2, may also play a role in cell survival
and proliferation of lung cancer cells if expressed.
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Figure 5. RNA-Seq of lung cancer cell lines shows expression of BTK-C.
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Materials and Methods
Cell Culture
Cell line A549 (non-small cell lung cancer) was obtained from the American Type
Culture Collection. These cells were found to express BTK (X. Wang unpublished).
Lung cancer cells were cultured in Dulbecco’s Modified Eagle Medium (gibco) (500 mL
total stock) supplemented with 10% Fetal Bovine Serum and 1% of Penicillinstreptomycin (Cellgro).
Chemicals and Biologicals
BTK inhibitors were used in a cell viability assay to check for drug effectiveness
in killing A549 cells. Ibrutinib was purchased from ChemieTek, AVL-292, also known as
Spebrutinib, was purchased from MedKoo Biosciences, Erlotinib, an EGFR inhibitor,
was purchased from Tarceva. Lapatinib, a HER2 inhibitor, was purchased from
TYKERB. Each drug was dissolved and diluted in DMSO.
Immunoblot
To confirm the expression of BTK in A549 cells, an immunoblot analysis was
necessary. Cell extracts were prepared using non-denaturing lysis buffer (20 𝜇𝜇M Tris

(pH 8.0), 137 mM NaCl, 10% glycerol, 1% Triton X-100, 2 𝜇𝜇M EDTA), supplemented

with complete cocktail of proteinase inhibitors (Roche). Protein extracts were separated
by SDS-PAGE, transferred to Immobilon-FL (Millipore, Billerca, MA) membranes and
immunoblotted according to standard protocols. Primary monoclonal anti-BTK
antibodies (E-9) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA).
Secondary anti-rabbit IgG-HRP antibodies (sc-2204, Santa Cruz Biotechnology) were
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used for imaging the immunoblot, using the iBrightTM CL1000 Imaging System®
(Thermofisher)

Cell Survival Assay
Approximately 5000 A549 cells per well were grown in a 96-well plate and
treated with BTK-inhibitors and growth factor inhihibtors. Cells were treated with 10 nM,
1 µM, 10 1 µM. and 30 µM of each inhibitor diluted in DMSO. Control cells were treated
with DMSO alone and cell proliferation continued without treatment. When the control
wells reached ~80% confluency, the cells were fixed with 5% formaldehyde, washed
with 1X PBS, and nuclei were stained with Hoechst 33342 (Molecular Probes®
Invitrogen). Cell images were obtained using an IN Cell Analyzer 2200 (GE Healthcare)
high content imaging system, with at least 9 fields imaged per single well of each
experiment. Cell numbers were determined using IN Cell Investigator 3.4 high content
image analysis software (GE Healthcare).
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Results
Immunoblot Analysis
The purpose of the immunoblot was to assess for BTK-C expression in A549
cells, and identify its function in signaling pathways. Due to time constraints, results for
the immunoblot could not be obtained in time before the completion of this thesis. The
immunoblot procedure was attempted four times but BTK-C did not appear on the
transfer membrane upon imaging. Despite not being able to obtain results from the
immunoblot, from the RNA-seq analysis of lung cancer cell transcriptomes (Figure 5),
there is reason to suspect expression of BTK-C in the A549 cell line.
Cell Survival Assay
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